Table 1 Application of aptamer and chemotherapeutics combination strategies in the therapy of pancreatic cancer
From: Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
S.No. | Aptamer | Drug | Targeting ligand | In vivo model | Route of administration | Cell line | Result | Ref. |
|---|---|---|---|---|---|---|---|---|
1. | Wnt5a and FZD7 | Gemcitabine | ABCG2 | – | – | Capan-2 | Wnt5a-induced resistance of gemcitabine in pancreatic tumour cells. | [98] |
2. | APTA-12 | Gemcitabine | Nucleolin | Mouse | Intravenous | Capan-1 | Considerably increased targeting affinity and suppression of cancer cell growth. | [96] |
3. | P12FR2 | 2′-fluoropyrimidine | PAUF | Mouse | Intraperitoneal | CFPAC-1 | Inhibit metastasis and cell proliferation | [99] |
4. | E07 | Gemcitabine | EGFR | – | – | MiaPaCa-2 and HPAF-2 | Targeted therapy increases effectiveness and reduce side effects. | [100] |
5. | AS1411 | AuNS | Nucleolin | – | – | PANC-1 | Increase cell death and caspase activity in tumour cells. | [101] |
6. | AP1153 | CPSNPs | CCKBR | Mouse | Intraperitoneal | PANC-1 | Enhanced delivery and absorption to pancreatic tumour cells. | [102] |
7. | Waz and E07 | MMAE and MMAF | EGFR, TfR | – | – | Panc-1, MIA PaCa-2, and BxPC3 | Delivery of hazardous payloads specifically to pancreatic tumour cells. | [103] |
8. | Ap52 | Doxorubicin | MAGE-A3 | Mouse | Intravenous, In situ | AsPC-1 | Provide targeted drug delivery and combined modulation of cell immunity for cancer treatment. | [104] |
9. | NF-κB | Doxorubicin | TfR | – | – | MIA PaCa-2 | Improving the Dox-mediated apoptotic impact in the pancreatic cancer cells. | [105] |
10. | P19 | Gemcitabine, 5-FU and MMAE | – | – | – | AsPC-1 | Significantly reduced cell growth and produced mitotic G2/M phase arrest. | [106] |